UltraSight closed a $24 million Series B2 round this week. The money goes toward wider U.S. hospital adoption and toward new workflows for intensive care and circulatory support.
Alive HealthTech Growth Fund led the round. Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures joined, alongside existing backers Mayo Clinic Ventures, NYU and Iron Nation.
The Israeli company sells Echosystem, a combination of structured training, real-time guidance during the scan and analytics that lets trained clinical providers, rather than cardiologists alone, capture focused echocardiograms under physician oversight. More than 10 commercial sites use it today, including intensive care units.
The clinical case rests on access rather than novelty. Focused cardiac ultrasound answers specific questions quickly, but the pool of people who can hold a probe correctly is small. UltraSight’s argument is that software can carry part of that skill.
Supporting evidence comes from a JAMA Cardiology study the company cites, which reported 93% sensitivity and 96% specificity for detecting moderate or worse aortic stenosis. Chief executive Davidi Vortman said the FDA-cleared portfolio is expanding to support broader cardiac imaging workflows.
Cardiac AI is crowded, and buying committees increasingly ask for deployment evidence rather than accuracy tables. The new money is earmarked for two things that answer that demand: more U.S. sites, and workflows where a fast image changes a treatment decision within minutes.
